Role of Innate Immunity in Non-Cystic Fibrosis Bronchiectasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-04-30

Study Completion Date

2018-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to demonstrate that 1) the secretion of mucins, antimicrobial peptides and Toll-like receptors is altered in certain patients with non-CF bronchiectasis, which makes them more susceptible to be infected by potentially pathogenic bacteria (PPB); and 2) the electronic nose is able to detect patterns of specific Volatile Organic Compounds (VOC) for patients with non-CF bronchiectasis colonized by PPB.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bronchial Infection in Patients With COPD and Frequent Exacerbations.

NCT03259022

Pulmonary Disease, Chronic Obstructive

UNKNOWN

E-nose Utility in the Diagnosis of Bacterial Infection in COPD

NCT01976117

Pulmonary Disease, Chronic Obstructive (COPD)

UNKNOWN NA

Mechanisms of Lung Defense and Their Relationship With Airway Infection in Chronic Obstructive Pulmonary Disease (COPD)

NCT01976130

Bacterial Infection in COPD

UNKNOWN NA

Prevention of OM-85 on Bronchiectasis Exacerbation

NCT01968421

Bronchiectasis With Acute Exacerbation

COMPLETED PHASE4

Bacteriology and Inflammation in Bronchiectasis

NCT01761214

Bronchiectasis

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prospective, observational study, which will include 50 patients with non-CF bronchiectasis who will be followed for a period of 12 months. A follow up control will be performed every three months to all patients, consisting in medical record, lung function tests, blood and serum collection, sputum analysis and culture, and collection of exhaled air for analysis using an electronic nose. These tests will also be repeated whenever the patient has an exacerbation. At the beginning and end of the study, a high resolution chest CT will be performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchiectasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-CF Bronchiectasis

Cyranose® 320

Intervention Type DEVICE

Detection of patterns of specific Volatile Organic Compounds in exhaled air

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cyranose® 320

Detection of patterns of specific Volatile Organic Compounds in exhaled air

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of non- CF bronchiectasis based on at least 1 lobe with bronchial dilatation and compatible clinical symptoms such as cough, sputum production and respiratory infections.
* Signed informed consent.

Exclusion Criteria

* Presence of exacerbation in the last 4 weeks.
* Antibiotic treatment in the last 4 weeks
* Use of oral corticosteroids in the last 4 weeks
* Concomitant terminal illness.
* Current cigarette smoking
* Active allergic bronchopulmonary aspergillosis
* Diagnosis of tuberculosis or active non-tuberculous Mycobacterial infection

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No